Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen

Breast Journal

Volumn 13, Issue 4, 2007, Pages 337-345

  Muss, Hyman B ^a,d   Bunn, Janice Yanushka ^a   Crocker, Abigail ^a   Plaut, Karen ^a   Koh, James ^a   Heintz, Nick ^a   Rincon, Mercedes ^a   Weaver, Donald L ^a   Tam, Diane ^a   Beatty, Barbara ^a   Kaufman, Peter ^b   Donovan, Michael ^c   Verbel, David ^c   Weiss, Linda ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c Aureon Biosciences   (United States)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

Adjuvant; Breast cancer; Cyclin D 1; Early stage; HER 2; Interleukin 6; Predictive factors; Tamoxifen; TGF beta

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; INTERLEUKIN 6; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; SUPPORT VECTOR MACHINE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR VOLUME; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CYCLIN D1; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, STEROID; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TAMOXIFEN;

EID: 34250882656     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00440.x     Document Type: Article

References (29)

1. Anonymous. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1998 351: 1451 67.
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998 339: 1609 18.
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005 365: 1687 717.
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244: 707 12.
5. Carlomagno C, Perrone F, Gallo C, et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996 14: 2702 8.
6. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000 18: 3471 9.
7. Yamauchi H, Stearns V, Hayes DF. The Role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 2001 8: 171 83.
8. Guyon I, Weston J, Barnhill S, Vapnik V. Gene selection for cancer classification using support vector machines. Mach Learn 2002 46: 389 422.
9. Byvatov E, Schneider G. Support vector machine applications in bioinformatics. Appl Bioinformatics 2003 2: 67 77.
10. Cristianini N, Shawe-Taylor J. An Introduction to Support Vector Machines and Other Kernel-Based Learning Methods. Cambridge, UK: Cambridge University Press, 2002.
11. Hastie T., Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York, NY: Springer, 2001.
12. Mukherjee S, Tamayo P, Slonim D, et al. Support vector machine classification of microarray data. 2000. Boston: Massachusetts Institute of Technology. Technical Report, Artificial Intelligence laboratory.
13. Brown MP, Grundy WN, Lin D, et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci USA 2000 97: 262 7.
14. Chang RF, Wu WJ, Moon WK, Chou YH, Chen DR. Support vector machines for diagnosis of breast tumors on US images. Acad Radiol 2003 10: 189 97.
15. Barlow J, Yandell D, Weaver D, Casey T, Plaut K. Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors. Breast Cancer Res Treat 2003 79: 149 59.
16. Lilenfeld DE, Stolley PD. Foundations of Epidemiology. New York, NY: Oxford University Press, 1994.
17. Markowska J, Wiktorowicz K, Szewierski Z, Madry R. The value of determining the interleukin-6 levels in epithelial ovarian cancer. Ann N Y Acad Sci 1995 762: 446 9.
18. Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 2003 48: 82 4.
19. Speirs V, Kerin MJ, Walton DS, Newton CJ, Desai SB, Atkin SL. Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells. Br J Cancer 2000 82: 1312 6.
20. Zwijsen RM, Wientjens E, Klompmaker R, van der SJ, Bernards R, Michalides RJ. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997 88: 405 15.
21. Michalides R, van Tinteren H, Balkenende A, et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002 86: 402 8.
22. Sutherland RL, Musgrove EA. Cyclin E and prognosis in patients with breast cancer. N Engl J Med 2002 347: 1546 7.
23. Barnes DM. Cyclin D1 in mammary carcinoma [Review] [31 refs]. J Pathol 1997 181: 267 9.
24. van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997 150: 705 11.
25. Sun L, Chen C. Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 1997 272: 25367 72.
26. Chen C, Wang XF, Sun L. Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem 1997 272: 12862 7.
27. Daidone MG, Luisi A, Martelli G, et al. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000 82: 270 7.
28. Ellis PA, Makris A, Burton SA, et al. Comparison of MIB-1 proliferation index with S-phase fraction in human breast carcinomas. Br J Cancer 1996 73: 640 3.
29. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004 351: 2817 26.